Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-031862
Filing Date
2022-11-14
Accepted
2022-11-14 14:19:05
Documents
50
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 740852
2 ex31-1.htm EX-31.1 18295
3 ex31-2.htm EX-31.2 18857
4 ex32-1.htm EX-32.1 10623
  Complete submission text file 0001493152-22-031862.txt   3840670

Data Files

Seq Description Document Type Size
5 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ptix-20220930.xsd EX-101.SCH 30585
6 INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ptix-20220930_cal.xml EX-101.CAL 42516
7 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ptix-20220930_def.xml EX-101.DEF 146007
8 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ptix-20220930_lab.xml EX-101.LAB 283639
9 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ptix-20220930_pre.xml EX-101.PRE 215220
44 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 538140
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12555 | Film No.: 221383743
SIC: 7389 Services-Business Services, NEC